The auto finance turnaround story, with Q2 earnings on July 17 and a meaningful gap to analyst consensus, is the cleanest catalyst on the list this week, but a beer company trading at a historically cheap cash flow multiple and a life sciences sum-of-parts play with Elliott Management pushing for action are both equally worth your attention.

You can get ahead of all three before the July earnings season closes the window.

Gaming and Entertainment

Churchill Downs (NASDAQ: CHDN), a racing and gaming company running the Kentucky Derby venue, TwinSpires digital wagering, and Historical Racing Machine venues in Kentucky and Virginia, trades around $84 to $88 against a fair value estimate of roughly $134, a gap of about 36%. The stock is down 23% year-to-date despite Q1 delivering an EBITDA margin above 38% and a 20% EPS beat.

The business is a scaled gaming platform, not a horse racing operator. HRM venues drove Q1 growth, Marshall Yards is ramping, and TwinSpires posted record Derby Week wagering. The stock gets priced like a racetrack, while the revenue increasingly looks like a gaming company with a famous annual event attached.

Q2 results in late July are the next concrete catalyst, and the core gaming segments do not move with consumer sentiment the way a traditional retailer does.

HRM Revenue Is Doing the Heavy Lifting

The Historical Racing Machine venues in Kentucky and Virginia are the fastest-growing part of the business, with new ETG products showing encouraging early customer response. These are recurring, high-margin gaming revenue streams that the Derby-focused market framing systematically undervalues.

Q1 Beat Sets the Bar for Late July

Beating estimates by 20% in Q1, while management described record Derby Week EBITDA, tells you the business delivered above expectations when it mattered. Q2 in late July is the next data point on whether that execution continues.

Consumer Defensive

Molson Coors Beverage (NYSE: TAP), a global brewer running Coors Light, Miller Lite, Coors Banquet, and Blue Moon, trades around $39 to $40, down 17% year to date, with a cash flow multiple well below the broader beverage industry and a dividend yield of 4.5% against an industry average of 2.8%. Q1 delivered EPS nearly double the prior year with a beat on both lines.

The bear case is simple and well-priced. Beer volumes are soft, GLP-1 headwinds exist, and analysts have been trimming targets. That is exactly when a company posting strong earnings growth at a trough multiple starts attracting attention. Coors Banquet has been a consistent winner and Q2 in late July or early August is the next checkpoint.

At 6.24x EV/EBITDA with a dividend covered at a low cash payout ratio, the price already reflects a lot of bad news that did not show up in Q1.

EV/EBITDA Is the Valuation Argument in One Line

The cash flow multiple puts this well below the broader beverage industry, suggesting you are paying a trough price on a business that just grew earnings sharply. That disconnect tends to close when it becomes clear the volume headwinds are cyclical rather than permanent.

Q1 Beat and Coors Banquet Momentum Are Doing the Talking

EPS improving significantly year over year while Coors Banquet gains share tells you parts of the portfolio are working even when the headline volume picture looks soft. The Q2 print will either confirm this is durable or challenge it.

Life Sciences

Bio-Rad Laboratories (NYSE: BIO), a global developer of life science research and clinical diagnostics products, trades with a market cap near $7 billion while holding a stake in Sartorius AG worth approximately $5 billion.

Elliott Investment Management disclosed a significant stake in May 2026 and has been pushing management to address the Sartorius position. The math is the story: the holding is worth roughly 70% of the entire company, which means the core diagnostics business trades at a fraction of what it should be worth on a standalone basis.

Q1 revenue came in slightly above consensus, though full-year guidance was trimmed due to geopolitical headwinds. RBC Capital resumed coverage with an Outperform rating, pointing to a sales recovery in 2027, and the completed buyback program retired nearly 10% of shares outstanding. Any announcement on the Sartorius stake or portfolio moves forces a repricing conversation.

Sartorius Stake Is Worth Most of the Market Cap

A single holding worth roughly 70% of the entire company leaves the core diagnostics business priced at close to zero by the market today. Elliott’s intervention is specifically targeted at addressing that gap.

Elliott and RBC Alignment Is an Unusual Double Signal

An activist pushing a clear asset monetization plan and an independent research firm resuming coverage with an Outperform rating and 2027 recovery outlook are both signaling conviction in the same direction. That kind of external alignment tends to matter when closing a sum-of-parts discount.

Ally Financial (NYSE: ALLY)

Ally just posted its best quarter in years with Q1 adjusted EPS up 90% year over year, net income of $319 million swinging from a prior-year loss, and retail auto delinquencies improving for four consecutive quarters.

The stock trades below analyst consensus with Q2 earnings arriving July 17, where if net interest margin expands toward the guided range and credit metrics keep improving, the call gives the market a reason to close the gap.

The credit cycle narrative that crushed this stock over the past two years is now running in reverse, and the Q2 print is the next piece of evidence that the turnaround is sticking. The risk is that consumer credit deteriorates in the second half before the NIM expansion story has time to fully play out.

Kenvue (NYSE: KVUE)

Kenvue runs Tylenol, Neutrogena, Listerine, and Band-Aid under a J&J consumer spinoff structure, trades well below its DCF fair value, and pays a dividend yield of 4.5% while the activist-driven restructuring takes shape.

Starboard Value disclosed a stake and pushed for board seats, cost cuts have been announced, and the new CEO brings expertise specifically aimed at e-commerce acceleration. Q2 earnings in early August are the next checkpoint on whether the margin improvements the activist thesis depends on are showing up.

The risk is that GLP-1 adoption compresses consumer wellness categories faster than the cost restructuring can compensate.

Yum China (NYSE: YUMC)

Yum China operates over 18,000 KFC and Pizza Hut restaurants across China, trades with net cash on the balance sheet and an accelerated buyback authorization, and Q2 results are expected in early August as same-store sales continue stabilizing.

The stock carries a meaningful discount to its historical multiple and to US restaurant peers on a free cash flow basis, with unit growth still running double digits.

Any sign that China consumer data is holding rather than declining moves this stock given how much pessimism is in the price. The risk is that China's consumer sentiment deteriorates further before the same-store sales stabilization the thesis requires.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any [blank] stocks you want me to check out.

Best Regards,
—Noah Zelvis
Undervalued Edge